Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities
- PMID: 23876845
- DOI: 10.1016/j.clml.2013.05.003
Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities
Abstract
Background: A major conclusion drawn from the accumulated cytogenetic data on solid tumors and some hematologic malignancies is that tumors progress by the acquisition of chromosomal changes, as reflected by more aggressive tumors containing a larger number of chromosomal abnormalities. An additional observation is that some chromosomal changes appear early in the disease progression, and some others appear late.
Material and methods: On the basis of this information, a model for karyotypic evolution in chronic lymphocytic leukemia (CLL) is presented. The Mitelman Database of Chromosomes in Cancer was searched, and 1749 abnormal karyotypes were assessed. The main clones were analyzed, and chromosomal gains and losses were used to design a model of genetic acquisition based on the calculation of a variable called time to occurrence (TO).
Results: Our comprehensive study of genetic abnormalities in a large number of CLL karyotypes revealed that most CLL has 2 chromosomal aberrations at diagnosis. Moreover, the temporal analysis suggests that trisomy 12 is an early event in the biological evolution of CLL.
Conclusion: These results highlight the possibility of targeted therapies affecting the genes located on this chromosome (cyclin D, cyclin D2, cyclin-dependent kinase 2, and cyclin-dependent kinase 4).
Keywords: Chromosome banding analysis; Chronic lymphocytic leukemia (CLL); Trisomy 12; del(13q).
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
-
Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities.N Engl J Med. 1990 Sep 13;323(11):720-4. doi: 10.1056/NEJM199009133231105. N Engl J Med. 1990. PMID: 2201915 Clinical Trial.
-
Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia.Cytometry B Clin Cytom. 2008 May;74(3):139-49. doi: 10.1002/cyto.b.20390. Cytometry B Clin Cytom. 2008. PMID: 18061951
-
Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.Int J Mol Med. 2006 May;17(5):769-78. Int J Mol Med. 2006. PMID: 16596259
-
Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes.Leukemia. 1997 Apr;11 Suppl 2:S19-24. Leukemia. 1997. PMID: 9178833 Review.
-
Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia.Best Pract Res Clin Haematol. 2007 Sep;20(3):439-53. doi: 10.1016/j.beha.2007.02.006. Best Pract Res Clin Haematol. 2007. PMID: 17707832 Review.
Cited by
-
Combined somatic mutation and copy number analysis in the survival of familial CLL.Br J Haematol. 2018 Jun;181(5):604-613. doi: 10.1111/bjh.15239. Epub 2018 Apr 24. Br J Haematol. 2018. PMID: 29687880 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources